NTRB

Nutriband Inc.

$5.76

-3.36%
SectorHealthcareIndustryBiotechnologyCountryUnited States
OverviewAI BriefChartFinancialsExposureFilingsScoresNewsAnalystsInsidersOwnership

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Source: Yahoo Finance
Q-Score54/ 100
Market Cap$70M
P/E—
Dividend Yield0.00%
52-Week Range—
Next Earnings—
AnalystsBuy+160.4% target
Beta0.85
AI summary

Price & performance

1M-12.0%
3M+124.9%
YTD+44.7%
1Y-4.8%
52-week range—
Beta0.85
Full chart and returns against a benchmark

Q-Score

54/ 100

Quality against peers; 50 is the peer median.

Growth59
Risk53
Performance71
Valuation37
Profitability35
Leverage61
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2026

Revenue$2M-4.8%
Net income-$8.2M
Net margin-404.1%+85.9 pts
Historical fundamentals

Red flags in filings

1active red flag
Material weakness in controlsApr 29, 2026
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Non Us0%
Regions, segments, customers and suppliers

Valuation

NTRBIndustryP/E—89.69P/S43.2811.88EV/EBITDA—67.10P/B13.146.22PEG—4.02
Dividend yield0.00%
Every valuation metric